Alle Studien
RekrutierungPHASE1INTERVENTIONELL

First in Human Study of CDR404 in HLA-A*02:01 Participants With MAGE-A4 Expressing Solid Tumors

This is a very early-stage study looking at a new experimental drug, CDR404, for certain advanced solid cancers that have a specific marker called MAGE-A4. These are cancers that haven't responded well to standard treatments. This is the first time CDR404 is being given to people, so the main goals are to check if it's safe and what dose works best. Researchers will also look for early signs that the treatment might be shrinking tumors. Participants will need to have a specific genetic marker (HLA-A*02:01) and their cancer must have the MAGE-A4 marker for them to be considered for the study.

Auf einen Blick

Status
Rekrutierung
Phase
PHASE1
Sponsor
CDR-Life AG
Einschreibeziel
42
Starten
24. Mai 2024
Geschätzte Fertigstellung
31 Dez 2027

Worum geht es in dieser Studie?

Imagine your body's immune system as a strong army that fights off invaders like viruses and bacteria. Sometimes, cancer cells can hide from this army. This study is testing a new, experimental medicine called CDR404, which is designed to help your immune system find and attack certain cancer cells more effectively. This specific medicine works by targeting a particular protein called MAGE-A4, which is found on some types of advanced solid cancers. It acts like a 'buddy' system, bringing your immune cells closer to the cancer cells so they can recognise and destroy them.

This is a 'first-in-human' study, which means it’s the very first time this new medicine is being given to people. Because of this, the most important goals are to make sure the treatment is safe and to find the right dose. The researchers will also be carefully watching to see if there are any early signs that the medicine is helping to shrink the cancer. They will also look at how the body handles the medicine.

This type of research is really important because it helps scientists learn about new ways to treat cancers that are difficult to treat with current standard options. While it's early days, studies like this pave the way for new cancer treatments in the future.

Wichtige Erkenntnisse

  • New experimental medicine for certain advanced solid cancers.
  • First time testing this medicine in people, focusing on safety and dosage.
  • Targets cancers with a specific marker called MAGE-A4.
  • Requires participants to have a specific immune system marker (HLA-A*02:01).
  • May offer a new option for hard-to-treat cancers.
  • Die Teilnahme ist freiwillig, und Sie können jederzeit zurücktreten.

Wer könnte berechtigt sein?

To be considered for this study, you would need to meet several important criteria. Firstly, your doctors would need to confirm that your cancer has a specific marker known as MAGE-A4. Your blood would also be tested to show you have a particular immune system marker called HLA-A*02:01. Your cancer should be advanced, meaning it has spread or cannot be removed by surgery, and it should no longer be responding well to, or you can't tolerate, standard treatments.

You would also need to be generally well, able to perform daily activities with ease, and have your body organs working properly. If you are a woman who could become pregnant, you would need to agree to use effective contraception during the study. The study is for adults aged 18 and over.

There are also some reasons why you might not be able to join. For example, if your cancer has spread to your brain and is causing symptoms, or if you've recently had major surgery. You wouldn't be able to participate if you have serious heart problems, an active infection needing antibiotics, or certain uncontrolled long-term health conditions like active hepatitis, HIV that could lead to AIDS, or an autoimmune disease requiring treatment. Being pregnant or breastfeeding would also exclude you from participating.

Könnte diese Studie für Sie geeignet sein?

Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.

  1. Is your cancer an advanced solid tumour?
  2. Has your cancer stopped responding to, or can you not tolerate, standard treatments?
  3. Have your doctors confirmed your cancer has the MAGE-A4 marker?
  4. Do you know if you have the HLA-A*02:01 immune marker?
  5. Are you generally well and able to perform daily activities?
  6. Are you an adult aged 18 or older?
Beantworten Sie jede Frage, um Ihr Ergebnis zu sehen.

Was beinhaltet die Teilnahme?

If you decide to join this study, you would receive the experimental medicine, CDR404. What taking part involves would depend on the specific stage of the study you are in, but generally, it would include: regular visits to the clinic for check-ups, blood tests, and scans to monitor your health and how the treatment is affecting your cancer. You would also have tests to see how your body processes the medicine and how your immune system responds to it. The clinic visits would likely be more frequent at the beginning of the study, becoming less frequent over time. The total duration of your participation would be discussed with you by the study team, and you would have follow-up appointments even after you stop receiving the medication. Specific details about the frequency of visits and assessments would be fully explained before you agree to participate.

Potenzielle Risiken und Vorteile

As with any medical study, there are potential benefits and risks. A potential benefit could be that the experimental medicine might help to control or shrink your cancer, especially if standard treatments haven't worked well. However, because this is an early-stage study, we don't know for certain if it will be effective. Potential risks include side effects from the experimental medicine, which could range from mild to more serious; these would be carefully monitored by the study team. You would be fully informed of all known and potential risks before deciding to join. Remember, taking part in a clinical trial is always voluntary, and you have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Locations (20)

  • Universität von Miami
    Verifizierte Postleitzahl
    Miami, Vereinigte Staaten· Zurückgezogen
  • Universität von Michigan
    Verifizierte Postleitzahl
    Ann Arbor, Vereinigte Staaten· Zurückgezogen
  • Providence Cancer Institute
    Verifizierte Postleitzahl
    Portland, Vereinigte Staaten· Rekrutierung
  • Pennsylvania Hospital
    Verifizierte Postleitzahl
    Philadelphia, Vereinigte Staaten· Rekrutierung
  • Universitair Ziekenhuis Antwerpen
    Verifizierte Postleitzahl
    Antwerp, Belgium· Rekrutierung
  • Institut Jules Bordet
    Verifizierte Postleitzahl
    Brüssel, Belgien· Rekrutierung
  • Cliniques Universitaires Saint-Luc, UCL Ouvain
    Verifizierte Postleitzahl
    Brüssel, Belgien· Rekrutierung
  • Universitair Ziekenhuis Gent
    Verifizierte Postleitzahl
    Gent, Belgien· Rekrutierung
  • Rigshospitalet
    Verifizierte Postleitzahl
    Copenhagen, Denmark· Rekrutierung
  • Istituto Clinico Humanitas
    Verifizierte Postleitzahl
    Mailand, Italien· Rekrutierung
  • Isituto Europeo di Oncologia (IEO)
    Verifizierte Postleitzahl
    Mailand, Italien· Rekrutierung
  • Hospital Universitari Vall d'Hebron
    Verifizierte Postleitzahl
    Barcelona, Spanien· Rekrutierung

Häufige Fragen

What does 'first-in-human' mean?

It means this is the very first time this new medicine is being tested in people. This type of study focuses on safety and finding the right dose.

What is MAGE-A4?

MAGE-A4 is a specific protein that can be found on the surface of some cancer cells. This new medicine is designed to target cells that have this protein.

What is HLA-A*02:01?

This is a common marker on some people's immune cells. You'd need to have this particular marker in your body for the medicine to work as intended.

Will this medicine cure my cancer?

This is an early-stage study, so it's too soon to say if this medicine will cure cancer. The main goals are to check safety and look for early signs of how it affects cancer.

Was passiert, wenn ich mich während der Studie unwohl fühle?

The study team will closely monitor you. You should always tell them about any new or worsening symptoms you experience.

Wie Sie mehr erfahren können

Dimitrios Chondros Chief Medical Officer, CDR-Life

Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.

Interessiert daran, teilzunehmen?

Registrieren Sie Ihr Interesse

Teilen Sie Ihre Details und das Forschungsteam für "First in Human Study of CDR404 in HLA-A*02:01 Participants W… wird Sie kontaktieren, wenn Sie möglicherweise infrage kommen. Sprechen Sie immer mit Ihrem Hausarzt, bevor Sie zustimmen, teilzunehmen.

Diskussion

Community-Diskussion

Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.